文献速递关节外科骨质疏松与代谢性骨病创伤骨科

双膦酸盐使用可能与初次全髋关节置换术后假体周围骨折风险增加相关

Bisphosphonate Use May be Associated With an Increased Risk of Periprosthetic Hip Fracture.
PubMed 文献 · J Arthroplasty · 2023-08-14

基于2010至2020年全国数据库,纳入30,137例初次择期全髋关节置换术前存在骨质疏松的患者,经1:1匹配后比较双膦酸盐使用组与未使用组各9,844例的2年结局。双膦酸盐使用与2年假体周围骨折率显著升高相关(OR 1.29,95%CI 1.04-1.61,P=.022),任何翻修风险有增加趋势(OR 1.19,95%CI 1.00-1.41,P=.056),感染、无菌性松动、脱位和死亡率无统计学差异。

要点

  • 骨质疏松患者初次全髋置换前使用双膦酸盐与2年假体周围骨折风险升高相关(OR 1.29)。
  • 双膦酸盐使用与任何翻修风险增加呈趋势(OR 1.19,P=.056),未达统计学显著。
  • 感染、无菌性松动、脱位和死亡率在两组间无统计学差异。

核心结论

  • 在骨质疏松患者中,初次全髋关节置换术前使用双膦酸盐是假体周围骨折的独立危险因素。
  • 需要更长期数据以确定该关联的潜在机制并识别预防措施。

研究设计与样本

  • 利用全国数据库识别2010年至2020年间初次择期全髋关节置换术前存在骨质疏松的患者30,137例。
  • 排除非择期全髋关节置换及使用糖皮质激素或其他骨质疏松药物的患者。
  • 双膦酸盐使用者与未使用者按年龄、性别、Elixhauser合并症指数及肥胖、类风湿关节炎、吸烟、酗酒史进行1:1匹配。
  • 采用Kaplan-Meier和多因素分析比较匹配后9,844例患者的两组2年结局。

主要发现

  • 匹配队列共9,844例患者,双膦酸盐使用与2年假体周围骨折率显著升高相关(OR 1.29,95%CI 1.04-1.61,P=.022)。
  • 双膦酸盐使用与任何翻修风险增加呈趋势(OR 1.19,95%CI 1.00-1.41,P=.056)。
  • 双膦酸盐使用者与未使用者的感染、无菌性松动、脱位和死亡率无统计学差异。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 需要更长期数据以确定该关联的潜在机制并识别预防措施。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Osteoporosis is common among patients undergoing primary total hip arthroplasty (THA). This study aimed to evaluate the effect of bisphosphonate treatment on osteoporotic patients undergoing primary THA. METHODS: Using a national database, 30,137 patients who had osteoporosis before primary elective THA were identified during 2010 to 2020. Patients undergoing nonelective THA and those using corticosteroids or other medications for osteoporosis were excluded. Bisphosphonate users and bisphosphonate naïve patients were matched 1:1 based on age, sex, Elixhauser comorbidity index, and a history of obesity, rheumatoid arthritis, tobacco use, and alcohol abuse. Kaplan-Meier and multivariate analyses were used to compare 2-year outcomes between groups. RESULTS: Among matched cohorts of 9,844 patients undergoing primary THA, bisphosphonate use was associated with a significantly higher 2-year rate of periprosthetic fracture (odds ratio 1.29, 95% confidence interval 1.04 to 1.61, P = .022). There was a trend toward increased risk of any revision with bisphosphonate use (odds ratio 1.19, confidence interval 1.00 to 1.41, P = .056). Rates of infection, aseptic loosening, dislocation, and mortality were not statistically different between bisphosphonate users and bisphosphonate-naïve patients. CONCLUSION: In osteoporotic patients, bisphosphonate use before primary THA is an independent risk factor for periprosthetic fracture. Additional longer-term data are needed to determine the underlying mechanism for this association and identify preventative measures.

来源:J Arthroplasty,查看原文。版权归原作者所有。

引用

  1. Serino J, Terhune EB, Harkin WE, et al. Bisphosphonate Use May be Associated With an Increased Risk of Periprosthetic Hip Fracture. J Arthroplasty. 2023. PMID: 37586595. doi:10.1016/j.arth.2023.08.029

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。